Abingdon Health seeks distributors for newly launched Seralite - FLC diagnostic device

Jul 17 2015

Following the commercial launch of Seralite® - FLC Abingdon Health is looking to appoint distributors in order to enable as many people as possible affected by multiple myeloma (a cancer arising from plasma cells) to have access to, and benefit from its rapid diagnostic capabilities.

Seralite® - FLC is a rapid diagnostic device for the quantitative measurement of kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) in serum as an aid to the diagnosis and management of multiple myeloma. The assay provides an accurate picture of disease status in 10 minutes. Using a simple to use, portable, rapid test, clinicians are able to monitor patients in "real time" supporting faster decision making.

There is an underlying requirement both for clinicians and patients for a test that can:
•Provide rapid results at diagnosis
•Monitor response to therapy and identify relapse in a "real time" situation.
•Identify response or lack or response to treatment
•Facilitate the stratification and monitoring of MGUS patients
Use of Seralite can facilitate:
•Reduced waiting time for results
•Earlier diagnosis for improved patient outcome
•Fewer clinic visits
•Peace of mind for patient

Source: Abingdon Health